AHMEDABAD, India, November 10, 2017 /PRNewswire/ --
Approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for treatment of:
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia," said Mr. Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."
Saroglitazar (Lipaglyn™) is a novel PPAR?/? agonist having predominant PPAR alpha activity. The recommended dose of Lipaglyn™ is 4 mg once-a-day. Lipaglyn™ is a prescription drug and should be taken under guidance of a registered medical practitioner. Lipaglyn™ was first launched in India during September 2013. Over the last several years, more than 500,000 patients have been treated with Lipaglyn™ in India, and data has been presented at several scientific and medical conferences.
About Zydus
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 21,000 people worldwide, including 1200 scientists engaged in R & D, and is dedicated to creating healthier communities globally. http://www.zyduscadila.com
Media Contact: Sujatha Rajesh [email protected]
SOURCE Zydus Cadila
Advertisement
Approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for treatment of:
- Dyslipidemia in patients with diabetes mellitus type 2.
- Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins
Advertisement
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia," said Mr. Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."
Saroglitazar (Lipaglyn™) is a novel PPAR?/? agonist having predominant PPAR alpha activity. The recommended dose of Lipaglyn™ is 4 mg once-a-day. Lipaglyn™ is a prescription drug and should be taken under guidance of a registered medical practitioner. Lipaglyn™ was first launched in India during September 2013. Over the last several years, more than 500,000 patients have been treated with Lipaglyn™ in India, and data has been presented at several scientific and medical conferences.
About Zydus
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. The group employs over 21,000 people worldwide, including 1200 scientists engaged in R & D, and is dedicated to creating healthier communities globally. http://www.zyduscadila.com
Media Contact: Sujatha Rajesh [email protected]
SOURCE Zydus Cadila
